Drug Overview
Risperdal Consta (Johnson & Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin (5-HT2), and alpha-2 adrenergic receptors. Risperdal Consta is the long-acting injectable formulation of Johnson & Johnson’s oral drug Risperdal.
Risperdal was initially approved for bipolar disorder in the US in 2003. Johnson & Johnson later launched Risperdal Consta in the US in May 2009. In the following year, EU regulators denied Risperdal Consta approval for the treatment of bipolar disorder, which prompted Johnson & Johnson to abandon the development program in these markets. The drug is also approved for the treatment of schizophrenia.
Risperdal Consta (Johnson & Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin (5-HT2), and alpha-2 adrenergic receptors. Risperdal Consta is the long-acting injectable formulation of Johnson & Johnson’s oral drug Risperdal.
Risperdal was initially approved for bipolar disorder in the US in 2003. Johnson & Johnson later launched Risperdal Consta in the US in May 2009. In the following year, EU regulators denied Risperdal Consta approval for the treatment of bipolar disorder, which prompted Johnson & Johnson to abandon the development program in these markets. The drug is also approved for the treatment of schizophrenia.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Risperdal Consta: Bipolar disorder
Risperdal Consta: Schizophrenia
List of Figures
Figure 1: Risperdal Consta for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for Risperdal Consta in bipolar disorder
Figure 3: Drug assessment summary for Risperdal Consta in bipolar disorder
Figure 4: Risperdal Consta for schizophrenia - SWOT analysis
Figure 5: Drug assessment summary of Risperdal Consta for schizophrenia
Figure 6: Drug assessment summary of Risperdal Consta for schizophrenia
Figure 7: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Risperdal Consta bipolar disorder indication approvals
Table 2: Risperdal Consta drug profile
Table 3: Risperdal Consta pivotal trial data in bipolar disorder
Table 4: Adverse reactions in =5% of Risperdal Consta-treated adult patients with bipolar disorder
Table 5: Risperdal Consta drug profile
Table 6: Risperdal Consta pivotal trial data in schizophrenia
Table 7: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017-26
